Visceral fat accumulation is an important determinant of PAI-1 levels in young, nonobese men and women: modulation by cross-sex hormone administration.
about
Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance.Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditionsGene expression in visceral and subcutaneous adipose tissues.Obesity, haemostasis and the fibrinolytic system.Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents.Adipose tissue quantification by imaging methods: a proposed classification.Circulating concentrations of monocyte chemoattractant protein-1, plasminogen activator inhibitor-1, and soluble leukocyte adhesion molecule-1 in overweight/obese men and women consuming fructose- or glucose-sweetened beverages for 10 weeksPlasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies.Do changes in sex steroid hormones precede or follow increases in body weight during the menopause transition? Results from the Study of Women's Health Across the Nation.The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis.Adipose tissue metabolism, diabetes and vascular disease--lessons from in vivo studies.The usefulness of circulating adipokine levels for the assessment of obesity-related health problemsThe determinants of plasma plasminogen activator inhibitor-1 levels differ for American and Japanese men aged 40-49.Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses.Intraabdominal fat, insulin sensitivity, and cardiovascular risk factors in postpartum women with a history of preeclampsia.Men and women, so different, so similar: observations from cross-sex hormone treatment of transsexual subjects.Is diabetes a hypercoagulable state? A critical appraisal.Oestrogen and anti-androgen therapy for transgender women.Cross-sex hormone therapy in transgender persons affects total body weight, body fat and lean body mass: a meta-analysis.Plasminogen activator inhibitor-1 and tissue-plasminogen activator in minority adolescents with type 2 diabetes and obesity.Weight, fat mass, and central distribution of fat increase when women use depot-medroxyprogesterone acetate for contraception.Plasminogen activator inhibitor type 1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines.Weight reduction is associated with increased plasma fibrin clot lysis.Relationship between resistin and aPAI-1 levels with insulin resistance in Saudi children.NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?Metabolic and functional changes in transgender individuals following cross-sex hormone treatment: Design and methods of the GEnder Dysphoria Treatment in Sweden (GETS) studyInsulin resistance but not visceral adipose tissue is associated with plasminogen activator inhibitor type 1 levels in overweight and obese premenopausal African-American women
P2860
Q33950656-D9982C7A-7AAB-4030-B890-1FA5CAC429F4Q34217461-118A6763-29CE-442E-B81B-83D724654C6FQ34454561-D171AE37-3CA5-4570-A837-3B31C848152CQ34743382-6FE945AE-CEB5-4843-98EC-F1216D495294Q34986710-2257D4CE-5D32-4490-85FC-F7ADC4A9243DQ35046039-0FAF09D3-BB10-4303-B8C8-8EE2F362E432Q35597938-5A9A5076-3496-4F79-9A5B-DFEC4E020BF7Q35905154-C9304389-6281-496C-A12F-D14D81650A7BQ36201486-052AC808-F9F5-4982-8951-2B959104ECEEQ36325519-EB368458-DF1C-4427-9B8E-3C8BC8BEE8E0Q36511220-D48C8649-61A2-43ED-AB1D-6FC26A309407Q36859053-652942FB-E346-4A09-BDAC-23B28E89C1F5Q36864352-141ED73C-C54B-4D62-9E25-1CDF62AB4B28Q37497438-989D34BA-B1A7-4688-8F01-F2EC034D7F70Q37530315-96FFE04F-DF17-4B13-8EF7-A60C3720F9D3Q38107528-1C4B9E8A-8C83-4F4E-AD88-77FDE0986803Q38409740-D0407FD1-2726-42E8-9E29-318B81B7140BQ38787403-8B1C938A-5CD2-4128-A4BA-C1B36F27F613Q40602937-6628E539-E273-4D26-AAE3-F8AD59ED0D04Q46497280-BBE7BEC2-88EF-42C3-83AF-1B55D8A476F9Q46583291-C3175A45-7B65-4C92-BB06-E8E29CEA8B32Q46675079-CE91B5A5-75E2-483E-8AA3-571BA06C998BQ46769026-FC9FF475-E039-49DC-A55C-E12DEA73EC3AQ51407387-1D83F4D3-83D6-4630-A88A-93A843CC11ADQ54232638-7CDF440B-2036-4ACF-9E29-0883FB679853Q57399098-E82445C3-B9AF-492F-81F0-D65AA0495F99Q57590484-62A01E03-B2DB-4058-9EE3-64F0BA545F19
P2860
Visceral fat accumulation is an important determinant of PAI-1 levels in young, nonobese men and women: modulation by cross-sex hormone administration.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Visceral fat accumulation is a ...... ss-sex hormone administration.
@en
Visceral fat accumulation is a ...... ss-sex hormone administration.
@nl
type
label
Visceral fat accumulation is a ...... ss-sex hormone administration.
@en
Visceral fat accumulation is a ...... ss-sex hormone administration.
@nl
prefLabel
Visceral fat accumulation is a ...... ss-sex hormone administration.
@en
Visceral fat accumulation is a ...... ss-sex hormone administration.
@nl
P2093
P1476
Visceral fat accumulation is a ...... ss-sex hormone administration.
@en
P2093
Asscheman H
Kooistra T
Stehouwer CD
P304
P356
10.1161/01.ATV.18.11.1716
P407
P577
1998-11-01T00:00:00Z